

FORM PTO-1449 (modified)  
To: U.S. Department of Commerce  
(PW FORM PAT-1449)  
Patent and Trademark Office



Atty.  
Dkt. No.

M#

Client Ref.

037003-0275463

1992-30-0029CP2

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: Anderson, et al.

Appln. No.: 08/921,060

Filing Date: August 29, 1997

Date: October 14 2003

Page

1

of

2

Examiner: Schwadron, R.

Group Art Unit: 1644

## U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
M1	AR 5,648,267	07/1997	Reff	435	320.1	
	BR					

## FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
					Enclosed	No
M1	CR 0 125 023 A1	11/1984	EP	Cabilly, et al.		
	DR 0 125 023 B1	11/1984	EP	Cabilly, et al.		
	ER 0 125 023 B2	03/2002	EP	Cabilly, et al.		
	FR 0 173 494 A2	03/1986	EP	Morrison, et al.		
	GR WO 88/04936	07/1988	WO	Robinson, et al.		
	HR					

## OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

	Adams, R.A. et al., Direct Implantation and serial transplantation of human acute lymphoblastic leukemia in hamsters, <i>SB-2, Can Res</i> 28:1121-1125 (1988).			
	Adams, Richard, Formal Discussion: The role of transplantation in the experimental investigation of human leukemia and lymphoma, <i>Can. Res.</i> 27:2479-2482 (1967).			
	Appelbaum, F.R., Radiolabeled Monoclonal Antibodies in the Treatment of Non-Hodgkin's Lymphoma, <i>Hem. Onc. Clinics of N.A.</i> 5(5):1013-1025 (1991).			
M1	Armitage, J.O. et al., Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP), <i>Cancer</i> 50:1695 (1982).			
	Boulianne, G.L. et al., Production of functional chimaeric mouse/human antibody, <i>Nature</i> 312:643 (December 1984).			
M1	Brunner, K.T. et al., Quantitative assay of the lytic action of immune lymphoid cells on <sup>51</sup> Cr-labeled allogeneic target cells <i>in vitro</i> ; inhibition by isoantibody and drugs, <i>Immunology</i> 14:181-189 (1968).			
	Chomczynski, P. et al., Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction, <i>Anal. Biochem.</i> 162:156-159 (1987).			
	Eary, J.F. et al, Imaging and Treatment of B-Cell Lymphoma, <i>J. Nuc. Med.</i> 31/8:1257-1268 (1990).			
M1	Einfeld, D.A. et al., Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains, <i>EMBO</i> 7:711 (1988)			
	Goldenberg, D.M. et al., Targeting, dosimetry and radioimmunotherapy of B-Cell lymphomas with iodine-131-labeled LL2 monoclonal antibody, <i>J. Clin. Onc.</i> 9/4:548-564 (1991).			
	Kaminski, M.G. et al., "Radioimmunotherapy of B-cell lymphoma with [ <sup>131</sup> I] anti-B1 (anti-CD20) antibody, <i>NEJM</i> 329/7 (1993).			

*[Handwritten signature]*

11/24/2007

M1	Liu, A.Y. et al., Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20 with Potent Fc-Dependent Biologic Activity. <i>J. Immun.</i> 139/10:3521-3526 (1987).				
	<del>Marx, Antibodies made to order, <i>Science</i> 229 455 (August 1985).</del>				
	<del>Morrison, S.L. et al., Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains, <i>PNAS</i> 81:6851-6854 (November 1984).</del>				
	<del>Morrison, Transfectomas provide novel chimeric antibodies, <i>Science</i> 229:1202-1207 (September 1985).</del>				
	<del>Münro, Uses of chimaeric antibodies, <i>Nature</i> 312:597 (December 1984).</del>				
	<del>Neuberger, M.S. et al., A hapten-specific chimaeric IgE antibody with human physiological-effector function, <i>Nature</i> 314:268 (March 1985).</del>				
	<del>*Press et al., Monoclonal antibody 1F5 (Anti-CD20) serotherapy of human B-cell lymphomas, <i>Blood</i> 69(2):584-591 (1987)</del>				
M1	Press, O.W. et al., "Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support." <i>New England Journal of Medicine</i> 329/17: 1219-12223 (1993).				
	<del>Press, O.W. et al., "Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody, <i>J. Clin. Onc.</i> 7/8:1027-1038 (1989)</del>				
880	<del>Robinson, R.D. et al., "Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities," <i>Hum. Antibod. Hybridomas</i> 2:84-93 (1991).</del>				
	<del>Sahagan et al., A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen, <i>J. Immunol.</i> 137:1066-1074 (1986).</del>				
M1	Scharff, M., The synthesis, assembly, and secretion of immunoglobulin: A biochemical and genetic approach, <i>Harvey Lectures</i> 69:125-143 (1974).				
M1	Shulman, M. et al., A better cell line for making hybridomas secreting specific antibodies, <i>Nature</i> 276:269 (1978).				
	<del>Srivastava, S.C., et al., Progress in research on ligands, nuclides and techniques for labeling monoclonal antibodies, <i>Nucl. Med. Bio.</i> 18(6): 589-603 (1991).</del>				
	<del>Sun, L.K. et al., Chimeric antibodies with 17-1A-derived variable and human constant regions, <i>Hybridoma</i> 5/1:517 (1986).</del>				
	<del>Tan et al., A human-mouse chimeric immunoglobulin gene with a human variable region is expressed in mouse myeloma cells, <i>J. Immunol.</i> 135:8564 (November 1985).</del>				
M4	Urlaub, G. et al., Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions." <i>Som. Cell &amp; Mol. Gen.</i> 12/6:555-566 (1986).				
M1	Valentine, M.A. et al., Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes, <i>J. Biol. Chem.</i> 264(19):11282-11287 (1989).				


Examiner

Date Considered:

11/24/2007

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified)  
To: U.S. Department of Commerce  
(PW FORM PAT-1449)  
Patent and Trademark Office



Atty.  
Dkt. No.

M#

Client Ref.

0275463

1992-30-0029CP2

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Applicant: ANDERSON *et al.*

Appln. No.: 08/921,060

Filing Date: August 29, 1997

Examiner: R. Schwadron

Group Art Unit: 1644

Date: December 3, 2003

Page

1

of

1

**U.S. PATENT DOCUMENTS**

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date
	MB	AR 6,183,744 B1	02/2001	GOLDENBERG	—	—	
	MB	BR 6,306,393 B1	10/2001	GOLDENBERG	—	—	
		CR					
		DR					
		ER					
		FR					

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
		GR					
		HR					
		IR					
		JR					
		KR					
		LR					

**OTHER**

	MB	MR	Kaminski, et al., "Radioimmunotherapy of Advanced B-Cell Lymphoma with Non Bone Marrow Ablative Doses of 131-I MB-1 Antibody," 1990, <i>Antibody Immunoconjugates, and Radiopharmaceuticals</i> , Vol. 3, No. 1, Abstract No. 83.
		NR	Kaminski, et al., "Radioimmunodetection (RID) and Non Marrow Ablative Radioimmunotherapy (RIT) of B-Cell Lymphoma With 131-I MB-1 Antibody," 1990, <i>Proceedings of ASCO</i> , Vol. 9, p. 271, Abstract No. 1051.
		OR	Wahl, et al., "Radioimmunotherapy of B-Cell Lymphoma with 131-I MB-1 Monoclonal Antibody," <i>The Journal of Nuclear Medicine: Proceedings of the 37<sup>th</sup> Annual Meeting</i> , p. 852, Abstract No. 622.
		PR	Kaminski, et al., "Phase I Trial Results of 131-I MB-1 Antibody Radioimmunotherapy (RAIT) of B-Cell Lymphoma," 1990, <i>Antibody Immunoconjugates, and Radiopharmaceuticals</i> , Vol. 4, No. 1, p. 36, Abstract No. 66.
		QR	Kaminski, et al., "Phase I Evaluation of 131-I MB-1 Antibody Radioimmunotherapy (RIT) of B-Cell Lymphoma," 1990, <i>Blood</i> , Vol. 76, No. 10, p. 355a, Abstract No. 1409.
	✓	RR	Kaminski, et al., "Imaging, Dosimetry, and Radioimmunotherapy With Iodine 131-Labeled Anti-CD37 Antibody in B-Cell Lymphoma," 1992, <i>Journal of Clinical Oncology</i> , Vol. 10, No. 11, pp. 1696-1711.
		SR	
		TR	
		UR	


Examiner

Date Considered:


11/24/2003

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified) To: U.S. Department of Commerce (PW FORM PAT-1449) Patent and Trademark Office				Atty. Dkt. No.	M#  0275463	Client Ref.  1992-30-0029CP2
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Applicant: ANDERSON et al.		
				Appln. No.: 08/921,060		
				Filing Date: August 29, 1997		
				Examiner: Schwadron, R.    Group Art Unit: 1644		
Date: March 18, 2004    Page 1 of 1						
<b>U.S. PATENT DOCUMENTS</b>						
Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date
	AR 5,595,721	04/1997	KAMINSKI			
MB	BR 5,439,665	08/1995	HANSEN			
MB	CR RE 38,008	02/2003	ABRAMS			
	DR 5,736,137	04/1998	ANDERSON			
MB	ER 5,776,456	07/1998	ANDERSON			
	FR 5,843,439	12/1998	ANDERSON			
	GR 6,399,061	06/2002	ANDERSON			
	HR 6,682,734	01/2004	ANDERSON			
<b>FOREIGN PATENT DOCUMENTS</b>						
Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available	
IR WO 94/11026	05/1994	PCT	ANDERSON			
JR						
KR						
LR						
MR						
<b>OTHER</b>						
*	NR	Grossbard M.L., et al., "Monoclonal antibody-based therapies of leukemia and lymphoma," <i>Blood</i> , 1992, 80:863-878.				
*	OR	Tedder T.F., et al., "Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes," <i>Eur J Immunol</i> , 1986, 16(8):881-87.				
*	PR	Tedder T.F., et al., "Cloning of a complementary DNA encoding a new mouse B lymphocyte differentiation antigen, homologous to the human B1 (CD20) antigen, and localization of the gene to chromosome 19," <i>J Immunol</i> , 1988, 141(12):4388-94.				
	QR					
	RR					
	SR					
	TR					
	UR					
Examiner:				Date Considered: 11/27/2007		
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.						



FORM PTO-1449 (modified)  
To: U.S. Department of Commerce  
(PW FORM PAT-1449)  
Patent and Trademark Office



Atty.  
Dkt. No.

M#

Client Ref.

0275463

1992-30-0029CP2

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Applicant: ANDERSON *et al.*

Appln. No.: 08/921,060

Filing Date: August 29, 1997

Examiner: R. Schwadron

Group Art Unit: 1644

Date: May 26, 2004

Page

1

of

1

**U.S. PATENT DOCUMENTS**

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date
	AR						
	BR						
	CR						
	DR						
	ER						
	FR						
	GR						
	HR						

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
	IR						
	JR						
	KR						
	LR						
	MR						
	NR						
	OR						
	PR						

**OTHER**

W3)	QR	<i>Idec Pharmaceuticals v. Corixa Corp.</i> , Case No. 01-1637-IEG [Doc. Nos. 486, 584] (S.D. Cal. Oct. 14, 2003).
W4)	RR	<i>Biogen Idec v. Corixa Corp.</i> , Case No. 01-1637-IEG [Doc. Nos. 635, 662, 486] (S.D. Cal. Jan. 22, 2004).
	SR	
	TR	
	UR	
	VR	
	WR	
	XR	
	YR	
	ZR	
	AAR	

Examiner

Date Considered:

11/24/2007

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.